|
|
| Nomenclature |
|
Symbol:
|
Tg(Prnp-ITM2B/APP695*42)A12Emcg
|
|
Name:
|
transgene insertion A12, Eileen McGowan
|
|
MGI ID: |
MGI:3710689 |
|
Synonyms: |
BRI-Abeta1-42, BRI-Abeta42A, BRI-Abeta42A line 12e, RI-Abeta42A (12e) |
|
Transgene:
|
Tg(Prnp-ITM2B/APP695*42)A12Emcg
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
(C3H x C57BL/6)F1 x C57BL/6
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The transgene was generated with a mouse prion promoter upstream of a BRI-Abeta42 fusion construct, containing a cDNA sequence from human type 2 transmembrane protein (BRI or ITM2B) fused in-frame with a "wildtype APP695" cDNA sequence encoding amyloid-beta42 (Abeta42) at the furin-like cleavage site; the C-terminal 23 amino acid ABri peptide of BRI was replaced with the Abeta42 sequence. Mice from the founder with the highest Abeta42 plasma levels, line BRI-Abeta42A (12e) were donated to the Jackson Laboratory. Transgenic fusion protein expression approximates levels of endogenous mouse APP expression and is expressed in patterns characteristic of the Prnp promoter, with highest expression in cerebellar granule cells and hippocampus. Full length Abeta fusion protein is most highly expressed with processed Abeta42 peptide expressed at lower levels (J:101023, J:120781)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
| References |
|
Original: |
J:101023
McGowan E et al.,
"Abeta42 is essential for parenchymal and vascular amyloid deposition in mice."
Neuron 2005 Jul 21;47(2):191-9
|
|
All: |
5 reference(s)
|
|
Analysis Tools
